Hong Zhang
About Hong Zhang
Hong Zhang is a Senior Principal Scientist in In Vivo Biology and Cancer Pharmacology at Bristol Myers Squibb in Cambridge, Massachusetts, with extensive experience in oncology and immuno-oncology research.
Title and Current Role
Hong Zhang holds the position of Senior Principal Scientist in the department of In Vivo Biology and Cancer Pharmacology at Bristol Myers Squibb. Based in Cambridge, Massachusetts, he is currently responsible for overseeing various research initiatives focused on cancer pharmacology.
Career at Bristol Myers Squibb
Hong Zhang has been working at Bristol Myers Squibb since 2019. He initially joined the company as a Principal Scientist, where he served for three years. Currently, he occupies the role of Senior Principal Scientist. His work involves leading projects in in vivo biology and cancer pharmacology, contributing significantly to the company's oncology drug development efforts.
Previous Experience at Takeda Oncology
Before joining Bristol Myers Squibb, Hong Zhang was employed at Takeda Oncology as a Scientist II in Cancer Pharmacology from 2017 to 2019. In this role, he was involved in critical research aimed at the development of new cancer therapies.
Educational Background
Hong Zhang received his Ph.D. in Biochemistry from Case Western Reserve University, where he studied from 2002 to 2008. Prior to that, he earned a Bachelor of Engineering (B.Eng.) in Biomedical Engineering from East China University of Science and Technology.
Expertise in Biomarker Discovery
With extensive experience in biomarker discovery, Hong Zhang has contributed to identifying novel biomarkers for cancer treatment. His work is crucial in the preclinical development of oncology drugs, from target identification to clinical candidate selection.
Experience in Translational Research
Hong Zhang has a strong background in translational research, effectively bridging the gap between laboratory findings and clinical applications. He has over a decade of experience in performing translational research, especially in the areas of oncology and immuno-oncology.